Reumatologia clinica最新文献

英文中文

Bibliometric analysis of the scientific production of rheumatology departments in Spain during the 2013-2022 period

Reumatologia clinica

Pub Date : 2025-01-01 DOI: 10.1016/j.reumae.2025.101807

Daniel Seoane-Mato , Fernando Sánchez-Alonso , Mercedes Guerra-Rodríguez , Enrique González-Dávila , Federico Díaz-González

Background and objective

Bibliometric studies of scientific production in Spanish Rheumatology are scarce. The aim of this study was to analyze the bibliographic production of Rheumatology Services in Spain over the period 2013-2022.

Materials and methods

Original articles and reviews with the affiliation of the first or corresponding author to a Spanish rheumatology Service/Department/Section/Unit were identified in the Web of Science Core Collection and Scopus databases. Keywords and titles were used to classify articles by field (clinical, epidemiological or basic) and pathology. International collaborations and collaborations between Autonomous Communities (AC) were identified. Quantitative bibliometric indicators were obtained (number of articles published per year, pathology and AC) and impact indicators were obtained (based on the number of citations per article). The H-index was also calculated.

Results

The total number of publications was 2321, with an annual growth rate of 4.1% in the period analyzed. In 14.1% of the articles there were international collaborations, mainly with the United States and the United Kingdom, while between ACs the most numerous were between Madrid and Catalonia. The pathologies with the highest H-index were rheumatoid arthritis (RA), spondyloarthropathies (SpA), osteoarthritis and vasculitis (34, 32, 28 and 26, respectively). The H-index for the Spanish rheumatology services as a whole was 69.

Discussion and conclusions

The scientific production of rheumatology services/departments/sections/units in our country increased between 2013 and 2022. By pathology, the scientific production in RA and SpA stands out.

{"title":"Bibliometric analysis of the scientific production of rheumatology departments in Spain during the 2013-2022 period","authors":"Daniel Seoane-Mato , Fernando Sánchez-Alonso , Mercedes Guerra-Rodríguez , Enrique González-Dávila , Federico Díaz-González","doi":"10.1016/j.reumae.2025.101807","DOIUrl":"10.1016/j.reumae.2025.101807","url":null,"abstract":"<div><h3>Background and objective</h3><div>Bibliometric studies of scientific production in Spanish Rheumatology are scarce. The aim of this study was to analyze the bibliographic production of Rheumatology Services in Spain over the period 2013-2022.</div></div><div><h3>Materials and methods</h3><div>Original articles and reviews with the affiliation of the first or corresponding author to a Spanish rheumatology Service/Department/Section/Unit were identified in the Web of Science Core Collection and Scopus databases. Keywords and titles were used to classify articles by field (clinical, epidemiological or basic) and pathology. International collaborations and collaborations between Autonomous Communities (AC) were identified. Quantitative bibliometric indicators were obtained (number of articles published per year, pathology and AC) and impact indicators were obtained (based on the number of citations per article). The H-index was also calculated.</div></div><div><h3>Results</h3><div>The total number of publications was 2321, with an annual growth rate of 4.1% in the period analyzed. In 14.1% of the articles there were international collaborations, mainly with the United States and the United Kingdom, while between ACs the most numerous were between Madrid and Catalonia. The pathologies with the highest H-index were rheumatoid arthritis (RA), spondyloarthropathies (SpA), osteoarthritis and vasculitis (34, 32, 28 and 26, respectively). The H-index for the Spanish rheumatology services as a whole was 69.</div></div><div><h3>Discussion and conclusions</h3><div>The scientific production of rheumatology services/departments/sections/units in our country increased between 2013 and 2022. By pathology, the scientific production in RA and SpA stands out.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 1","pages":"Article 101807"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143043987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrating different perspectives to define a concept of comprehensive remission in rheumatoid arthritis: The SUMAR project

Reumatologia clinica

Pub Date : 2025-01-01 DOI: 10.1016/j.reumae.2025.101800

Alejandro Balsa , José Luis Andreu , Juan Carlos Hermosa-Hernán , Josefa León-Navarro , Jordi Nicolas Pico , José Javier Pérez Venegas , Susana Romero-Yuste , Raimon Sanmarti , Antonio Ignacio Torralba Gómez-Portillo , Juan Carlos Valenzuela-Gámez , Jordi Cohen

Introduction and objectives

The SUMAR project aimed to establish a consensus on the concept of remission in patients with rheumatoid arthritis (RA) that takes into account the different perspectives of patients, health care professionals and health care managers.

Materials and methods

The scientific committee comprised a rheumatologist who acted as a national coordinator, 4 rheumatologists, 1 primary care physician, 1 nurse, 2 hospital pharmacists, 2 health care managers and 1 member of a patient advocacy group. The study was undertaken from 2020 to 2021 in three phases: (1) analysis of several perspectives on remission in RA with the participation of 275 patients, 160 rheumatologists and 31 health care managers; (2) an integrative definition of remission, which included two multidisciplinary workshops with 11 and 12 participants; and (3) extension and dissemination with up to 200 participants in 7 regional multidisciplinary meetings.

Results

The concept of remission in the different settings and by the different stakeholders was heterogeneous. It was agreed that, in addition to inflammatory activity, remission should include pain and functionality as well as the duration of remission. For the participants, the definition of remission varied depending on the clinical scenario, without or with structural damage, seeking to “normalize” the outcomes in the former and avoid progression in the latter. The implementation of the concept of comprehensive remission was considered less feasible, and the main barriers to implementation were the lack of time for consultation and the variability in information technology systems across the different autonomous communities.

Discussion and conclusions

This definition of remission is not only based on the concept of the presence or absence of inflammatory activity based on existing indexes, but also includes variables directly reported by the patient that are related to their health and quality of life.

{"title":"Integrating different perspectives to define a concept of comprehensive remission in rheumatoid arthritis: The SUMAR project","authors":"Alejandro Balsa , José Luis Andreu , Juan Carlos Hermosa-Hernán , Josefa León-Navarro , Jordi Nicolas Pico , José Javier Pérez Venegas , Susana Romero-Yuste , Raimon Sanmarti , Antonio Ignacio Torralba Gómez-Portillo , Juan Carlos Valenzuela-Gámez , Jordi Cohen","doi":"10.1016/j.reumae.2025.101800","DOIUrl":"10.1016/j.reumae.2025.101800","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>The SUMAR project aimed to establish a consensus on the concept of remission in patients with rheumatoid arthritis (RA) that takes into account the different perspectives of patients, health care professionals and health care managers.</div></div><div><h3>Materials and methods</h3><div>The scientific committee comprised a rheumatologist who acted as a national coordinator, 4 rheumatologists, 1 primary care physician, 1 nurse, 2 hospital pharmacists, 2 health care managers and 1 member of a patient advocacy group. The study was undertaken from 2020 to 2021 in three phases: (1) analysis of several perspectives on remission in RA with the participation of 275 patients, 160 rheumatologists and 31 health care managers; (2) an integrative definition of remission, which included two multidisciplinary workshops with 11 and 12 participants; and (3) extension and dissemination with up to 200 participants in 7 regional multidisciplinary meetings.</div></div><div><h3>Results</h3><div>The concept of remission in the different settings and by the different stakeholders was heterogeneous. It was agreed that, in addition to inflammatory activity, remission should include pain and functionality as well as the duration of remission. For the participants, the definition of remission varied depending on the clinical scenario, without or with structural damage, seeking to “normalize” the outcomes in the former and avoid progression in the latter. The implementation of the concept of comprehensive remission was considered less feasible, and the main barriers to implementation were the lack of time for consultation and the variability in information technology systems across the different autonomous communities.</div></div><div><h3>Discussion and conclusions</h3><div>This definition of remission is not only based on the concept of the presence or absence of inflammatory activity based on existing indexes, but also includes variables directly reported by the patient that are related to their health and quality of life.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 1","pages":"Article 101800"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Connecting the dots: Bilateral thigh pain, dental anomaly, recurrent pregnancy loss to a complex diagnostic journey

Reumatologia clinica

Pub Date : 2025-01-01 DOI: 10.1016/j.reumae.2025.101804

Sabarinath Mahadevan, Ishwarya Ramadoss, P.S. Arul Raja Murugan

引用次数: 0

Do patients with axial spondyloarthritis with active disease suffer from greater disease burden and work impairment? Results from the International Map of Axial Spondyloarthritis (IMAS) 伴有活动性疾病的轴性脊柱炎患者是否有更大的疾病负担和工作障碍？轴性脊柱炎国际地图（IMAS）结果

Reumatologia clinica

Pub Date : 2024-12-01 DOI: 10.1016/j.reumae.2024.11.009

Marco Garrido-Cumbrera , Denis Poddubnyy , Fernando Sommerfleck , Christine Bundy , Souzi Makri , José Correa-Fernández , Shashank Akerkar , Jo Lowe , Elie Karam , Victoria Navarro-Compán

Background

To assess the prevalence of clinically active disease in axial spondyloarthritis (axSpA) and its associated factors in a large global sample of patients from the International Map of Axial Spondyloarthritis (IMAS) study.

Methods

IMAS is a cross-sectional online survey (2017–2022) of 5557 axSpA patients. Patients were divided between those with active disease (BASDAI ≥4) and without active disease (BASDAI <4). The factors evaluated were sociodemographic, lifestyle, patient-reported outcomes, employment, disease characteristics, extra-musculoskeletal manifestations, and treatment. Logistic regression analysis stratified by gender were used to evaluate the relationship between investigated factors and active disease.

Results

In the present study, 5295 patients who had responded to the BASDAI scale were included in the present study: 3231 were from Europe, 770 from North America, 600 from Asia, 548 from Latin America, and 146 from Africa. The mean age was 43.8 ± 12.9 years and 55.4% were females. Patients reported a mean BASDAI of 5.4 (±2.1) with 75% having active disease (BASDAI ≥4). In South Africa, 87.0% of patients reported having active disease, compared to 68.5% in Asia. Multivariable logistic regression showed an association of active disease with higher functional limitation, greater spinal stiffness, difficulty finding a job due to axSpA and worse mental health in both genders. For males, younger age and shorter diagnostic delay, and for females, no physical activity and presence of inflammatory bowel disease were associated with active disease.

Conclusions

Three quarters of patients with axSpA reported clinically active disease, with higher proportion of patients with active disease in South Africa and lower proportion in Asia. Our results underline the complexity of the clinical disease activity concept in axSpA and the need for a holistic approach in the patient management, care and treatment.

背景：在国际轴性脊柱炎地图（IMAS）研究的全球大量患者样本中，评估轴性脊柱炎（axSpA）临床活动性疾病的患病率及其相关因素。方法simas是一项针对5557例axSpA患者的横断面在线调查（2017-2022）。患者分为活动性疾病组（BASDAI≥4）和非活动性疾病组（BASDAI <4）。评估的因素包括社会人口统计学、生活方式、患者报告的结果、就业、疾病特征、肌肉骨骼外表现和治疗。采用按性别分层的Logistic回归分析评价调查因素与活动性疾病的关系。结果本研究共纳入5295例对BASDAI量表有反应的患者，其中欧洲3231例，北美770例，亚洲600例，拉丁美洲548例，非洲146例。平均年龄43.8±12.9岁，女性占55.4%。患者报告BASDAI平均为5.4（±2.1），其中75%为活动性疾病（BASDAI≥4）。在南非，87.0%的患者报告患有活动性疾病，而亚洲为68.5%。多变量logistic回归显示，活动性疾病与较高的功能限制、较高的脊柱僵硬、由于axSpA导致的找工作困难以及较差的心理健康状况在两性中均存在关联。对于男性，较年轻和较短的诊断延迟，以及对于女性，没有身体活动和存在炎症性肠病与活动性疾病相关。结论3 / 4的axSpA患者报告临床活动性疾病，其中南非的活动性疾病比例较高，亚洲的比例较低。我们的研究结果强调了axSpA临床疾病活动概念的复杂性，以及在患者管理、护理和治疗中采用整体方法的必要性。

{"title":"Do patients with axial spondyloarthritis with active disease suffer from greater disease burden and work impairment? Results from the International Map of Axial Spondyloarthritis (IMAS)","authors":"Marco Garrido-Cumbrera , Denis Poddubnyy , Fernando Sommerfleck , Christine Bundy , Souzi Makri , José Correa-Fernández , Shashank Akerkar , Jo Lowe , Elie Karam , Victoria Navarro-Compán","doi":"10.1016/j.reumae.2024.11.009","DOIUrl":"10.1016/j.reumae.2024.11.009","url":null,"abstract":"<div><h3>Background</h3><div>To assess the prevalence of clinically active disease in axial spondyloarthritis (axSpA) and its associated factors in a large global sample of patients from the International Map of Axial Spondyloarthritis (IMAS) study.</div></div><div><h3>Methods</h3><div>IMAS is a cross-sectional online survey (2017–2022) of 5557 axSpA patients. Patients were divided between those with active disease (BASDAI ≥4) and without active disease (BASDAI <4). The factors evaluated were sociodemographic, lifestyle, patient-reported outcomes, employment, disease characteristics, extra-musculoskeletal manifestations, and treatment. Logistic regression analysis stratified by gender were used to evaluate the relationship between investigated factors and active disease.</div></div><div><h3>Results</h3><div>In the present study, 5295 patients who had responded to the BASDAI scale were included in the present study: 3231 were from Europe, 770 from North America, 600 from Asia, 548 from Latin America, and 146 from Africa. The mean age was 43.8±12.9 years and 55.4% were females. Patients reported a mean BASDAI of 5.4 (±2.1) with 75% having active disease (BASDAI ≥4). In South Africa, 87.0% of patients reported having active disease, compared to 68.5% in Asia. Multivariable logistic regression showed an association of active disease with higher functional limitation, greater spinal stiffness, difficulty finding a job due to axSpA and worse mental health in both genders. For males, younger age and shorter diagnostic delay, and for females, no physical activity and presence of inflammatory bowel disease were associated with active disease.</div></div><div><h3>Conclusions</h3><div>Three quarters of patients with axSpA reported clinically active disease, with higher proportion of patients with active disease in South Africa and lower proportion in Asia. Our results underline the complexity of the clinical disease activity concept in axSpA and the need for a holistic approach in the patient management, care and treatment.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 10","pages":"Pages 547-554"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Changes in immature granulocyte levels and their association with disease activation following biologic therapy in patients with ankylosing spondylitis 强直性脊柱炎患者生物治疗后未成熟粒细胞水平的变化及其与疾病激活的关系

Reumatologia clinica

Pub Date : 2024-12-01 DOI: 10.1016/j.reumae.2024.11.007

Burak Okyar , Servet Yüce , İbrahim Halil Bilen , Bekir Torun , İlyas Öztürk , Gözde Yıldırım Çetin

Introduction

AS is a chronic disease with an inflammatory serum microenvironment characterized by increased oxidative stress (OS). Along with OS, reactive oxygen species (ROS) are elevated in patients with AS. Overexpression of ROS causes active inflammatory processes leading to the secretion of pro-inflammatory factors, including tumor necrosis factor-alpha (TNF-α). Immature granulocytes (IG) are essential to the chronic inflammatory process. This may mean that IG can be a parameter used in the follow-up of chronic inflammatory diseases such as AS.

Objective

We aimed to evaluate the change in IG in patients with AS who were on biologic medication for six months after diagnosis and to assess its relationship with disease activity, remission, and BASDAI score.

Methods

This single-center, retrospective study was conducted between January 2020 and January 2022. For the study, 68 patients were included in the patient group and 74 patients in the control group. Demographic and laboratory data were recorded and compared in the groups. Then, the patient group was divided into two groups: pre-biologic drug and post-biologic drug. Hemogram data, IG, ESR, CRP, and BASDAI data were recorded for both groups. Correlation analysis was performed between the results of IG data and hemogram and laboratory data.

Conclusion

In our study, WBC, neutrophil, IG, and IG% ratios were significantly higher in AS patients compared to the control group. Neutrophil, IG, and IG% levels were significantly decreased in the AS group compared to pretreatment and post-treatment comparisons. In addition, IG levels were correlated with WBC, neutrophil, CRP, and ESR levels. This study hypothesized that IG values may be a valuable parameter for monitoring AS disease severity, response to treatment, and disease activation after biological drug use.

as是一种慢性疾病，其炎症性血清微环境以氧化应激（OS）增加为特征。随着OS的发生，AS患者的活性氧（ROS）升高。ROS的过度表达引起活跃的炎症过程，导致促炎因子的分泌，包括肿瘤坏死因子-α (TNF-α)。未成熟粒细胞（IG）对慢性炎症过程至关重要。这可能意味着IG可以作为慢性炎症性疾病如as的随访参数。目的：我们旨在评估诊断后6个月接受生物药物治疗的AS患者IG的变化，并评估其与疾病活动性、缓解和BASDAI评分的关系。方法本研究于2020年1月至2022年1月进行单中心回顾性研究。在这项研究中，68例患者被纳入患者组，74例患者被纳入对照组。记录并比较各组的人口统计和实验室数据。然后将患者组分为生物前用药组和生物后用药组。记录两组患者血象、IG、ESR、CRP及BASDAI数据。IG数据、血象图结果与实验室数据进行相关性分析。结论在我们的研究中，AS患者的WBC、中性粒细胞、IG和IG%比值明显高于对照组。与治疗前和治疗后比较，AS组的中性粒细胞、IG和IG%水平显著降低。此外，IG水平与WBC、中性粒细胞、CRP和ESR水平相关。本研究假设IG值可能是监测AS疾病严重程度、治疗反应和使用生物药物后疾病激活的有价值参数。

{"title":"Changes in immature granulocyte levels and their association with disease activation following biologic therapy in patients with ankylosing spondylitis","authors":"Burak Okyar , Servet Yüce , İbrahim Halil Bilen , Bekir Torun , İlyas Öztürk , Gözde Yıldırım Çetin","doi":"10.1016/j.reumae.2024.11.007","DOIUrl":"10.1016/j.reumae.2024.11.007","url":null,"abstract":"<div><h3>Introduction</h3><div>AS is a chronic disease with an inflammatory serum microenvironment characterized by increased oxidative stress (OS). Along with OS, reactive oxygen species (ROS) are elevated in patients with AS. Overexpression of ROS causes active inflammatory processes leading to the secretion of pro-inflammatory factors, including tumor necrosis factor-alpha (TNF-α). Immature granulocytes (IG) are essential to the chronic inflammatory process. This may mean that IG can be a parameter used in the follow-up of chronic inflammatory diseases such as AS.</div></div><div><h3>Objective</h3><div>We aimed to evaluate the change in IG in patients with AS who were on biologic medication for six months after diagnosis and to assess its relationship with disease activity, remission, and BASDAI score.</div></div><div><h3>Methods</h3><div>This single-center, retrospective study was conducted between January 2020 and January 2022. For the study, 68 patients were included in the patient group and 74 patients in the control group. Demographic and laboratory data were recorded and compared in the groups. Then, the patient group was divided into two groups: pre-biologic drug and post-biologic drug. Hemogram data, IG, ESR, CRP, and BASDAI data were recorded for both groups. Correlation analysis was performed between the results of IG data and hemogram and laboratory data.</div></div><div><h3>Conclusion</h3><div>In our study, WBC, neutrophil, IG, and IG% ratios were significantly higher in AS patients compared to the control group. Neutrophil, IG, and IG% levels were significantly decreased in the AS group compared to pretreatment and post-treatment comparisons. In addition, IG levels were correlated with WBC, neutrophil, CRP, and ESR levels. This study hypothesized that IG values may be a valuable parameter for monitoring AS disease severity, response to treatment, and disease activation after biological drug use.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 10","pages":"Pages 533-538"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vaccination against human papillomavirus in patients with immune-mediate diseases 为免疫性疾病患者接种人类乳头瘤病毒疫苗。

Reumatologia clinica

Pub Date : 2024-12-01 DOI: 10.1016/j.reumae.2024.11.005

Marco Tobar-Marcillo , Carlos Guerrero-Solís , Daniel Goyes-Burbano , Jorge Esteban Toro-Tobar

引用次数: 0

Epidemiology of systemic lupus erythematosus in Latin America 拉丁美洲系统性红斑狼疮的流行病学。

Reumatologia clinica

Pub Date : 2024-12-01 DOI: 10.1016/j.reumae.2024.11.003

Ivet Etchegaray-Morales , Claudia Mendoza-Pinto , Francisco Javier Arellano-Avendaño , Sandra Ibañez-Ovando , Pamela Munguía-Realpozo , Jacsiry Guadalupe Orbe-Sosa , Edith Ramírez-Lara , Mario García-Carrasco

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects several organs, causing significant morbidity and increased mortality. It’s more frequent in young, fertile women and can appear in all ethnic groups.

The worldwide prevalence report indicates that there are at least 5 million patients with SLE. Although this disease can be found in every geographic region, certain races are more affected, such as Afro-American, Hispanic, and Asian populations. Furthermore, most of the epidemiologic information comes from Europe or the USA. In Latin America, only a few countries have reported data, like Argentina, Colombia, or Mexico, and even in these countries, the numbers vary.

系统性红斑狼疮（SLE）是一种影响多个器官的慢性自身免疫性疾病，会导致严重的发病率和死亡率。它多发于年轻、有生育能力的女性，可出现在所有种族群体中。全球发病率报告显示，至少有 500 万系统性红斑狼疮患者。虽然这种疾病在各个地区都有发生，但某些种族的人受影响更大，如非洲裔美国人、西班牙裔美国人和亚洲人。此外，大多数流行病学资料都来自欧洲或美国。在拉丁美洲，只有阿根廷、哥伦比亚或墨西哥等少数几个国家报告了数据，即使在这些国家，数据也各不相同。

引用次数: 0

Utility of virtual reality in medical training: Clinical management of a patient with knee monoarthritis 虚拟现实在医学培训中的实用性：膝关节单关节炎患者的临床治疗。

Reumatologia clinica

Pub Date : 2024-12-01 DOI: 10.1016/j.reumae.2024.11.004

Javier de Toro Santos , Ana Isabel Turrión , Mariano Andrés Collado , M. Carmen San José Méndez , Roberto Rilo Antelo , Juan Antonio Juanes Méndez

The use of technological environments with virtual reality (VR) techniques for the practice of arthrocentesis offers an effective and safe way to learn and improve the necessary skills to carry out a medical procedure and patient care. This article presents an interactive simulator using immersive VR, in which the participant experiences practicing clinical management and decision-making in the face of a person presenting with monoarthritis in a medical consultation. The objective with this development is for the user to acquire the competence to perform, correctly and safely, a knee arthrocentesis and to differentiate the types of synovial fluids that can be found in a joint. In turn, it provides clinical guidance and assists with the user's medical decision-making. Therefore, the aim is to improve the quality of care and patient safety when practicing this technique previously through clinical simulation.

使用虚拟现实（VR）技术环境进行关节穿刺术的实践，为学习和提高实施医疗程序和护理病人的必要技能提供了一种有效而安全的方法。本文介绍了一种采用沉浸式 VR 技术的交互式模拟器，参与者可在其中体验临床管理和决策实践，以应对在医疗咨询中出现的单关节炎患者。这项开发的目的是让用户掌握正确、安全地进行膝关节穿刺术的能力，并区分关节内滑液的类型。反过来，它还能提供临床指导，协助用户做出医疗决策。因此，目的是通过临床模拟来提高护理质量和患者安全。

引用次数: 0

Eosinophilic granulomatosis with poliangiitis: Successful treatment with methotrexate and low-dose of mepolizumab 嗜酸性肉芽肿伴脊髓灰质炎：使用甲氨蝶呤和小剂量甲泼尼珠单抗治疗获得成功

Reumatologia clinica

Pub Date : 2024-12-01 DOI: 10.1016/j.reumae.2024.11.001

Luis Francisco Valdés-Corona , Patricia Aguilar-Dominguez , Ariel Jasqui-Bucay , Mariana Arroyo-Machiavelo

引用次数: 0

Psychosis as a manifestation in systemic lupus erythematosus: treatment and long-term results. Number of cases 作为系统性红斑狼疮一种表现的精神病：治疗和长期效果。病例数。

Reumatologia clinica

Pub Date : 2024-12-01 DOI: 10.1016/j.reumae.2024.11.002

Maria Joselin Rodarte-Gallegos, Ma. Azucena Ramos-Sánchez, Yadhira Mejia-Holguin, Ariana Maia Becerra-Márquez, Luciano Ortiz-Treviño

We present a case series of 5 patients with psychosis associated with SLE according to the ACR 1999 criteria. It presented as an initial clinical manifestation, clinically they had visual and auditory hallucinations, all the patients were women, average age 25 years, the accompanying manifestations were mostly mucocutaneous, articular and renal. Two patients presented antiphospholipid syndromes. The remission induction treatment was based on pulses of steroids and cyclophosphamide with a complete response in 4/5 patients, maintenance was left with mycophenolic acid and azathioprine.

我们根据1999年ACR标准，对5名系统性红斑狼疮伴发精神病的患者进行了病例系列研究。所有患者均为女性，平均年龄为25岁，伴随的表现主要是粘膜、关节和肾脏症状。两名患者出现了抗磷脂综合征。缓解诱导治疗以脉冲类固醇和环磷酰胺为基础，4/5 的患者获得了完全缓解，维持治疗以霉酚酸和硫唑嘌呤为主。

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Reumatologia clinica

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀